|
Rank
|
Events overall (n = 8602)
|
n
|
Weighted % (95% CI)
|
New events after phase 2 (n differs by condition)a
|
n
|
Weighted % (95% CI)
|
|---|
|
1
|
Gastrointestinal Disorders
|
482
|
5.62 (5.04, 6.19)
|
Gastrointestinal Disorders
|
303/8423
|
3.64 (3.17, 4.12)
|
|
2
|
Other Joint Disorders
|
467
|
5.60 (5.02, 6.18)
|
Other Joint Disorders
|
291/8426
|
3.38 (2.93, 3.83)
|
|
3
|
Arthritis/osteoarthritis
|
183
|
2.18 (1.82, 2.55)
|
Arthritis/osteoarthritis
|
131/8550
|
1.54 (1.23, 1.85)
|
|
4
|
Hypertension
|
151
|
2.02 (1.66, 2.37)
|
Hypertension
|
105/8556
|
1.38 (1.09, 1.68)
|
|
5
|
Prostate and other genitourinary disorder
|
158
|
1.94 (1.59, 2.29)
|
Prostate and other genitourinary disorder
|
90/8534
|
1.14 (0.87, 1.41)
|
|
6
|
Asthma/COPD
|
130
|
1.59 (1.27, 1.91)
|
Asthma/COPD
|
88/8560
|
1.01 (0.76, 1.26)
|
|
7
|
Back and neck pain
|
123
|
1.56 (1.25, 1.88)
|
Back and neck pain
|
76/8555
|
0.92 (0.68, 1.16)
|
|
8
|
Cancer and Tumours
|
99
|
1.30 (1.01, 1.59)
|
Cancer and Tumours
|
67/8570
|
0.89 (0.65, 1.14)
|
|
9
|
Migraine/headache
|
88
|
1.00 (0.75, 1.25)
|
Hyperlipidaemia
|
55/8589
|
0.72 (0.51, 0.94)
|
|
10
|
Hyperlipidaemia
|
68
|
0.90 (0.66, 1.14)
|
Migraine/headache
|
53/8567
|
0.68 (0.47, 0.89)
|
- aParticipants were excluded who had an APC event for that condition before phase 2 so the numbers reflect the numbers included in the later Cox regression analyses
